then, the E1684 high-dose IFN-a regimen (alternatively known as the Kirkwood regimen) has become the standard arm in any newly established randomized trial of adjuvant therapy undertaken in the USA in patients with stage IIB and III (American Joint Committee on Cancer staging system, AJCC) malignant melanoma.
IFN-ax was licensed for adjuvant use in melanoma in the UK in July 1997. However, significant controversy surrounds the rationale for using this expensive, potentially toxic therapeutic modality. Uncertainty hinges on the requirement for an adequate evidence base justifying treatment. Current clinical status of adjuvant IFN-a -arguments both for and against its use -are outlined here, with the intention of facilitating a move towards a consensus among those involved in melanoma patient care.
THE PATIENT POPULATION JUSTIFIES INVESTMENT OF RESOURCES
Malignant melanoma currently represents around 1% of all new cancer cases in the UK. Unlike the more common solid tumours, it is a disease often affecting young adults: median age at presentation is below 50 years (OPCS, 1994) . Furthermore, the incidence of melanoma is increasing at a rate faster than for any other Received 11 August 1997 Accepted 14 October 1997 Correspondence to: PG de Takats tumour, currently doubling every 6-10 years. Despite evidence that more individuals are presenting with localized, resectable disease, the death rate is increasing by around 5% per year. Malignant melanoma can behave unpredictably, but studies have shown that, for patients with thick primary tumours (> 4mm Breslow depth, T4, AJCC stage IIB tumours) and/or regional lymph node involvement (AJCC stage III tumours), over 50% of patients will relapse or die of recurrent disease within 2 years of surgery. When recurrent disease is not amenable to surgery, no medical therapy has yet been shown to impact on survival. Thus, while patients with disseminated disease are considered candidates for phase I trials of novel anti-cancer modalities, there is a clear imperative to define an effective adjuvant therapy that will reduce the risk of disease recurrence after primary melanoma surgery.
BIOLOGICAL AGENTS HOLD THE GREATEST PROMISE AS SYSTEMIC THERAPY
Conventional cytotoxics tested in patients with advanced disease have been shown to achieve response rates of, at best, 20-25% as single agents and 50-60% in dose-intensive combination regimens (reviewed in McClay and McClay, 1996) . However, no chemotherapy regimen to date has been shown to prolong patient survival significantly. Thus, single-agent dacarbazine (response rate around 20%) remains the mainstay of standard therapy outside clinical trials. Early randomized trials of adjuvant therapy in melanoma using dacarbazine (e.g. Kerin et al, 1995) , combination chemotherapy (e.g. Meisenberg et al, 1993) , bacille CalmetteGuerin (BCG; Tan and Ho, 1993) and other modalities, including levamisole (e.g. Parkinson, 1991; Spitler, 1991) and vitamin A (Meyskens et al, 1994) have not demonstrated any survival advantage with treatment compared with surgery alone.
There is now a wealth of evidence that the immune system can influence the natural history of melanoma, and a variety of biological agents has been shown to possess antitumour activity both in vitro and in vivo. Monoclonal antibodies raised against tumourspecific antigens (e.g. antigens encoded by the MAGE gene family, tyrosinase, Melan-A/MART), active immunotherapy by vaccination with, in particular, melanoma-specific gangliosides, and intensive biochemotherapy regimens are currently being explored in early clinical trials (Balch et al, 1997) . Considerable trial experience has already been gained with the type I (IFN-a and -, subtypes) and type II (IFN-y) interferons as well as interleukin 2 (IL-2), as single agents and in combination regimens, in both the advanced and the adjuvant setting. Recombinant IFN-a has shown broad-spectrum immunomodulatory and antiproliferative activity in a variety of human malignancies, including melanoma. Disappointingly, IFN-a appears to achieve overall response rates no better than the most active single-agent chemotherapy drugs (Tables 1 and 2 ). However, some 5% of patients consistently achieve complete responses, which appear to be durable, associated with long-term survival (Creagan et al, 1988;  Legha, 1997) . Despite more than a decade of trial work, the optimal dose and scheduling of IFN-a has not been established. Efficacy and toxicity appear to be both dose and time dependent: higher doses induce more complete responses of longer duration while being more toxic; delayed responses are documented after several months of treatment; a wide variety of recognized IFN-a-related side-effects limit tolerance of treatment (Table 3) .
DOES ADJUVANT INTERFERON OFFER SURVIVAL BENEFIT?
The early trials of adjuvant melanoma immunotherapy failed to show prolongation of patient survival (Fisher et al, 1981; Kaiser et al, 1981; Veronesi et al, 1982) , but the role of the recombinant IFNs had yet to be tested. All subtypes of IFN have now been explored to prevent melanoma recurrence after disease resection. IFN-y has shown minimal anti-tumour activity against melanoma, and the negative randomized trial of adjuvant IFN-y undertaken by the South West Oncology Group suggested possible adverse effects in the treatment arm (Meyskens et al, 1990 (Meyskens et al, , 1995 . Several trials of adjuvant IFN-a have been undertaken globally, and Table 4 summarizes completed and ongoing phase III IFN-a studies in high-risk patients. Until now, all such studies have randomized against an observation-only arm.
From current data available from these studies, the value of adjuvant IFN-a remains uncertain. The completed studies of low-dose therapy are not yet mature. However, two such studies have suggested possible patient benefit. The WHO melanoma Program Trial 16 study randomized 444 patients with histologically proven lymph node-positive disease between June 1990 and January 1994 to receive either IFN-a-2a 3 MU flat dose administered subcutaneously (s.c.) three times a week for 3 years, or no treatment after surgery. An early interim analysis indicated highly significant prolongation of disease-free survival for all treated patients and an overall survival benefit for some subgroups . However, 1 year later, the survival curves converged and the study has not shown durable survival benefit (Cascinelli, 1995) . The French Cooperative Group on Melanoma have evaluated the same drug and dose (but treatment period 18 months) in 499 patients with > 1.5-mm-thick primary lesions without clinically detectable lymph node involvement. The first published results, at median follow-up of 2.3 years, indicated no overall survival difference between treated and untreated patients (Grob et al, 1996) . However, by June 1995, at median follow-up of 3 years, a statistical prolongation of both relapse-free (P = 0.029, two-sided) and overall survival (P = 0.011, two-sided) was evident in favour of IFN-a therapy. The results of a 1997 reanalysis are awaited with interest. The only conventional phase I pharmacokinetic dose-escalation studies with IFN-a were undertaken by ECOG in the early 1980s. Assessing drug administered by either the intravenous (i.v.) or intramuscular (i.m.) route, they determined that 20 MU m-2 could be safely given to patients on a daily basis with manageable sideeffects (Kirkwood et al, 1985) . Thus, trials were undertaken to determine the role of much higher doses of IFN-a in the adjuvant setting.
The results of two high-dose studies have been published to date. E1684 has shown both statistically significant prolongation in disease-free and overall survival with adjuvant IFN-a-2b by 9 months and 12 months respectively . However, a study by the North Central Cancer Trials Group (NCCTG) randomized 262 patients with primary tumours > 1.69 mm thick or nodal involvement to receive IFN-a-2a 20 MU m-2 i.m. three times a week for 12 weeks. At median follow-up of 6.1 years, neither disease-free nor overall survival were significantly greater with treatment (Creagan et al, 1995) .
In the UK, currently, standard therapy for stage I-ITT melanoma remains surgical excision of tumour. Interested, motivated oncologists are likely to be offering high-risk patients entry to one of two ongoing phase III adjuvant IFN-a studies: the UKCCCRsponsored Aim High study randomizes patients on a 1:1 basis to receive either 'low-dose' IFN-a-2a (3 MU s.c. three times per week for 2 years) or to observation only; the EORTC 18952 study randomizes patients to receive either 'internediate-dose' IFN-a-2b (10 MU s.c. daily x5 for 4 weeks, followed by maintenance therapy with either 10 MU s.c. three times per week for 1 year or 5 MU s.c. three times per week for 2 years) vs observation. The EORTC study is skewed such that four in every five patients will receive IFN-a.
Both European studies were initiated at a time when the preliminary results of E1684 were known. At that time, a healthy scepticism among UK oncologists prevailed (Williams et al, 1997) ; the (Kirkwood et al, 1985) showed that, while IFN-a was detectable in serum after 24 h only after i.m. administration, significantly higher peak plasma concen- Morton et al (1992) as a means of detecting occult nodal metastases, and thus the offer of selective lymphadenectomy to those patients. Now combined with intraoperative use of a gamma probe to detect injected radioactive colloid in addition to blue dye, experienced operators are able to identify the sentinel node in 99% of cases. Various investigators have developed reverse transcription polymerase chain reaction methods to sensitively and specifically measure tyrosinase mRNA in sentinel lymph nodes (Wang et al, 1994) and to detect circulating melanoma cells in blood (Smith et al, 1991; Brossart et al, 1995) . The current USA and EORTC adjuvant studies are undertaking measurement of such molecular markers in primary tumour, lymph node tissue and blood of trial patients. What impact these kind of techniques will have in terms of patient selection for therapeutic intervention and subsequent survival outcome remains to be determined.
FINAL COMMENT
There is accumulating evidence demonstrating that the host's immunity influences melanoma behaviour. Recent clinical demonstration of survival benefit with adjuvant high-dose IFN-a, albeit in a single randomized clinical trial, was sufficient to justify licensing of IFN-a for adjuvant use in the UK and to persuade a growing number of specialists that this is the treatment of choice for selected patients at high risk of disease recurrence and, ipso facto, virtual certain death. But before oncologists protest the imperative for allocating limited resources to fund IFN-a, we must be sure that the quality of evidence in favour of treatment justifies the cost both to the health service and to the patient. If, on reviewing the evidence, uncertainty prevails, we have a duty to address the issues surrounding adjuvant melanoma therapy in a systematic, controlled manner within the context of well-designed clinical trials. Until such time as E1690 has been analysed, ongoing adjuvant studies (Aim High and EORTC 18952) should be supported, and the argument for financing of IFN-a justified in terms of facilitating clinical research of fundamental importance.
Experience with adjuvant melanoma trials performed to date suggests that patient recruitment is difficult. Thus, for future trials, co-operation with our USA and European colleagues is essential. By gaining unanimous support from within the oncology disciplines, we may better influence govemment, funding agencies, purchasers and industry for the right drug to be available to the right people at the right time.
